As the Centers for Medicare and Medicaid Services (CMS) works to implement the price-setting provisions created by the Inflation Reduction Act, the details of how the law is implemented will either exacerbate or mitigate the potential harms for patients.
Today, NPC submitted comments to the Centers for Medicare and Medicaid Services (CMS) to offer input on the agency’s latest efforts to define the process of collecting data to inform drug price-setting and subsequent discussions between CMS and biopharmaceutical manufacturers.
Like the comments that NPC submitted to CMS on April 14th in response to the agency’s initial implementation plan, today's comment letter highlights the pitfalls and potential for unintended consequences in the agency’s current efforts and steps that could help mitigate the harms of the law for patients. The letter highlights several key concerns that data collection requirements defined by CMS could:
- Create rigid requirements without necessary transparency
- Constrain the ability of manufacturers to convey important information about treatments
- Limit the accessibility of information for patients, caregivers and patient advocacy organizations engaged in the discussion
- Leave out elements of value that are important to patients and society
Learn more about the comment letter submitted by NPC.